Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1850119 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $2.19Day +8.42%Mkt cap $395M1Y +284.9%Off 52W high −28.0%Vol (1Y) 97.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 945 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest15.7% of sh out |
| Days to cover22.0d |
| 13F net flow (QoQ)+5.27% |
| Top-10 13F concentration72.7% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$114.9M |
| Earnings (TTM)-$107.8M |
| ROE−6.0% |
| Net margin−8.8% |
| ROIC−196.4% |
| Sales growth 3Y175.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+120.1% |
| 1Y+284.9% |
| 3Y−28.2% |
| Since incept. (ann.)−32.8% |
Total return through 2026-07-30 · series begins 2022-10-18. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)97.0% |
| Ann. volatility (3Y)89.9% |
| Sharpe (1Y)1.83 |
| Sharpe (3Y)0.30 |
| Max drawdown (1Y)−37.0% |
| Max drawdown (3Y)−92.7% |
| Beta (3Y vs SPY)2.65 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 17.8M | $40M | 9.88% | new |
| TCG Crossover Management, LLC | 17.8M | $39M | 9.88% | new |
| Versant Venture Management, LLC | 12.2M | $27M | 6.77% | new |
| Deep Track Capital, LP | 9.5M | $21M | 5.28% | new |
| RTW INVESTMENTS, LP | 8.7M | $20M | 4.84% | new |
| Venrock Adviser, LLC | 8.7M | $20M | 4.84% | new |
| Commodore Capital LP | 8.7M | $20M | 4.84% | new |
| Point72 Asset Management, L.P. | 6.0M | $13M | 3.32% | +0.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.11 | −112.4% | — | — |
| 2025-09-30 | 2025-11-13 | −$0.40 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.38 | — | — | — |
| 2025-03-31 | 2025-05-15 | $0.89 | — | $109.2M | +12667.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
